Table 3.
Assessment of therapeutic efficiency using TrxR, AFP, CA19-9, CEA and their combinations after chemotherapy in MLC patients.
| Tumor markers | MLCs after chemotherapy | ||||||
|---|---|---|---|---|---|---|---|
| AUC (95%CI) | SEN% | SPE% | PPV% | NPV% | PLR | NLR | |
| Metastatic carcinoma of liver: CUPs vs. CRPs | |||||||
| TrxR | 0.630 (0.542–0.718) | 63.93 | 63.00 | 63.34 | 63.59 | 1.73 | 1.75 |
| AFP | 0.544 (0.453–0.636) | 57.38 | 58.00 | 57.74 | 57.64 | 1.37 | 1.36 |
| CEA | 0.511 (0.417–0.605) | 13.11 | 97.00 | 81.38 | 52.75 | 4.37 | 1.12 |
| CA19-9 | 0.519 (0.427–0.611) | 24.59 | 84.00 | 60.58 | 52.69 | 1.54 | 1.11 |
| CEA + CA19-9 + AFP | 0.570 (0.476–0.663) | 63.93 | 53.00 | 57.63 | 59.51 | 1.36 | 1.47 |
| CEA + CA19-9 + AFP + TrxR | 0.643 (0.556–0.729) | 68.85 | 63.00 | 65.05 | 66.92 | 1.86 | 2.02 |
SPE: specificity; SEN: sensitivity; NPV: negative predictive value; PPV: positive predictive value;NLR: negative likelihood ratio. PLR: positive likelihood ratio; the diagnosic threshold of TrxR activity level was 8.285 U/mL in MLC patients.